Human antibodies targeting the C-type lectin-like domain of the tumor endothelial cell marker clec14a regulate angiogenic properties in vitro. - Wikidata - wikimedia - TriplyDB

Human antibodies targeting the C-type lectin-like domain of the tumor endothelial cell marker clec14a regulate angiogenic properties in vitro.

Human antibodies targeting the C-type lectin-like domain of the tumor endothelial cell marker clec14a regulate angiogenic properties in vitro.

http://www.wikidata.org/entity/Q37501825

about

Anti-angiogenic alternatives to VEGF blockade Blocking CLEC14A-MMRN2 binding inhibits sprouting angiogenesis and tumour growth Selection of scFv Antibody Fragments Binding to Human Blood versus Lymphatic Endothelial Surface Antigens by Direct Cell Phage Display.A Human Antibody That Binds to the Sixth Ig-Like Domain of VCAM-1 Blocks Lung Cancer Cell Migration In Vitro.Ig-like domain 6 of VCAM-1 is a potential therapeutic target in TNFα-induced angiogenesis Angiogenesis biomarkers and their targeting ligands as potential targets for tumor angiogenesis.Therapeutic targeting of tetraspanin8 in epithelial ovarian cancer invasion and metastasis.A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer Therapy CLEC14a-HSP70-1A interaction regulates HSP70-1A-induced angiogenesis.Multimerin-2 is a ligand for group 14 family C-type lectins CLEC14A, CD93 and CD248 spanning the endothelial pericyte interface.Expression of a novel endothelial marker, C-type lectin 14A, in epithelial ovarian cancer and its prognostic significance.Inhibition of VEGF-dependent angiogenesis and tumor angiogenesis by an optimized antibody targeting CLEC14a.

P2860

Q26775947-D35B2825-E0E3-4636-9F26-7E985B66DEA1 Q28116133-74F04747-7DDA-445C-A2A3-01A792889872 Q35628801-304C9E5C-347D-4D61-A3CE-7731F9DD63DA Q36300449-00CD9C7D-08BD-4FF6-8182-E75C85F884B9 Q37680056-B5DA1E70-BA6B-4497-9628-A2AF2E699F73 Q39368829-FA226621-DD87-4EEA-9433-410B2AB4E851 Q40068293-8387EF8C-0DB4-41E2-A12D-46AD78D91528 Q41574359-1599045E-50C0-418C-8570-A361C7FBD2E6 Q41629417-FBEF5D93-84DD-4FB7-9B5A-95E2B50AB9AB Q45391515-20C72F48-E865-4E04-A312-BEB437921A52 Q48091914-25498373-7A33-45A0-B1E0-38A84F2092BD Q50117760-6C7F5B42-BDE4-4163-91A2-5AC40A935EA1

P2860

Human antibodies targeting the C-type lectin-like domain of the tumor endothelial cell marker clec14a regulate angiogenic properties in vitro.

http://www.wikidata.org/entity/Q37501825

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 06 May 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Human antibodies targeting the ...... ngiogenic properties in vitro.

@en

Human antibodies targeting the ...... ngiogenic properties in vitro.

@nl

type

label

Human antibodies targeting the ...... ngiogenic properties in vitro.

@en

Human antibodies targeting the ...... ngiogenic properties in vitro.

@nl

prefLabel

Human antibodies targeting the ...... ngiogenic properties in vitro.

@en

Human antibodies targeting the ...... ngiogenic properties in vitro.

@nl

P1433

Q37501825-6E2C61FE-D57E-409C-BC86-A35B69481BA8

P1476

Q37501825-D0931C15-155F-4AC9-B093-07429577009F

P2093

Q37501825-06D71A26-BEFF-4D28-A022-40C83E513D7C

Q37501825-23CC69A0-2D02-45D3-B57B-3362056D6FE8

Q37501825-2CF78EDB-99EF-4F85-B6FE-8F913E73E0C5

Q37501825-6115E4AA-7945-4685-86E6-28DDCE3B9B3E

Q37501825-623E4BC1-107A-4ACE-A923-11B64A045D70

Q37501825-6A360BA6-EB5C-44BA-902C-53D0AD069F99

Q37501825-9FA65321-6603-4DA7-9B84-65488F003D7A

Q37501825-A12ACF8B-840E-4F5A-9AF6-9F861596ABAD

Q37501825-B6EF4611-7113-409E-8C21-315C050F3753

Q37501825-E17EE747-F806-4F77-8F38-FC1AF337ABF2

P2860

Q37501825-098912E2-AB3B-4963-B59C-AF1BC9FDFAAF

Q37501825-0D426EF2-9F5B-44F3-800F-8765BD8B3313

Q37501825-1428EA63-45FA-4F70-8037-0B8512A98D00

Q37501825-22B71F5C-9025-423E-89A8-39FEA7BCB4AE

Q37501825-23AE6690-0D66-47E9-9CDB-F6426A3F7E41

Q37501825-27349556-5E44-43F2-9D5D-4555BDD27F35

Q37501825-2F1DC6B7-77A1-4216-A44D-E706F70BC864

Q37501825-399EDADF-0758-463A-8803-B7224F471A7D

Q37501825-4F57EA80-BA5C-4554-A37D-F248E33A8006

Q37501825-5A4E0A85-71DA-4C6B-890E-B02D7E1EBBFD

P2888

Q37501825-95B70CED-F659-475C-8DF8-F42D6C594BB2

P304

Q37501825-FA7D2A02-0F3F-433C-A837-C909CA8F80A7

P31

Q37501825-4822FEC7-C779-4A17-94ED-230CB96A49FE

P356

Q37501825-777DC35E-2442-4A90-8AC4-6C7DEBBBD384

P407

Q37501825-FCEE89D3-916D-4662-B585-37791776DA97

P433

Q37501825-3FA63B30-21B1-4E24-9B5B-D8ED4BBBCE9D

P478

Q37501825-2BEF350E-8643-4678-A812-DD2CDEE98116

P577

Q37501825-04F077F2-ED6C-4F3F-9474-D26F2A50566B

P5875

Q37501825-9BCB739F-404B-4CB9-83D1-6F318C2CAE0A

P6179

Q37501825-0ADDC2FC-F9D7-477F-8DE6-7FEA39888942

P698

Q37501825-93938965-E8B7-4221-AB03-CD5B66982704

P921

Q37501825-5076E3AE-6430-4AF5-8E58-E843829138C1

Q37501825-D817E489-4E99-4824-BA1D-931B56185C21

P932

Q37501825-E3F2029A-4966-481B-A986-062536672BBF

P356

P1433

P1476

Human antibodies targeting the ...... ngiogenic properties in vitro.

@en

P2093

B D Song

http://www.w3.org/2001/XMLSchema#string

H J Hong

http://www.w3.org/2001/XMLSchema#string

H Shim

http://www.w3.org/2001/XMLSchema#string

J Chung

http://www.w3.org/2001/XMLSchema#string

J R Choi

http://www.w3.org/2001/XMLSchema#string

M H Jeoung

http://www.w3.org/2001/XMLSchema#string

M K Ki

http://www.w3.org/2001/XMLSchema#string

S Lee

http://www.w3.org/2001/XMLSchema#string

S-S Rho

http://www.w3.org/2001/XMLSchema#string

Y-G Kwon

http://www.w3.org/2001/XMLSchema#string

P2860

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Downstream processing of monoclonal antibodies--application of platform approaches

Angiogenesis in life, disease and medicine

A monoclonal antibody that inhibits translation in Sf21 cell lysates is specific for glyceraldehyde-3-phosphate dehydrogenase.

Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance

Production and characterization of chimeric monoclonal antibodies against Burkholderia pseudomallei and B. mallei using the DHFR expression system.

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.

From rolling to arrest on blood vessels: leukocyte tap dancing on endothelial integrin ligands and chemokines at sub-second contacts.

Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy

Angiogenesis: a target for cancer therapy.

P2888

P304

5449-5457

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/ONC.2013.156

http://www.w3.org/2001/XMLSchema#string

P407

P433

48

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236638687

http://www.w3.org/2001/XMLSchema#string

P6179

1027699651

http://www.w3.org/2001/XMLSchema#string

P698

23644659

http://www.w3.org/2001/XMLSchema#string

P921

P932

3898107

http://www.w3.org/2001/XMLSchema#string